04:53 AM EDT, 06/17/2024 (MT Newswires) -- Regeneron Pharmaceuticals ( REGN ) said Sunday long-term data from an early-to-mid-stage trial of its experimental therapy, linvoseltamab, showed that 50% of patients with relapsed/refractory multiple myeloma, a type of blood cancer, achieved a complete response while the overall response rate was 71%.

The study compared linvoseltamab with real-world standard-of-care treatment in clinical practice, with the latest data coming after 14-month median follow-up, the company said.

Additionally, 63% of patients achieved "a very good partial response" or better, the company said, citing a determination by an independent review committee.

Safety data at the 14-month median follow-up was generally consistent with that at the 11-month median follow-up. Six deaths, considered due to treatment-emergent adverse events by investigators, occurred on treatment or within 30 days of the last dose, with five due to infection and one due to renal failure, Regeneron said.

Price: 1,044.78, Change: +8.26, Percent Change: +0.80